Literature DB >> 31203290

Added Value of Contrast Medium in Whole-Body Hybrid Positron Emission Tomography/Magnetic Resonance Imaging: Comparison between Contrast-Enhanced and Non-Contrast-Enhanced Protocols.

Filiz Celebi1, Emetullah Cindil2, Dauren Sarsenov3, Bulent Unalan4, Cem Balcı5.   

Abstract

OBJECTIVE: To compare the diagnostic ability and time efficiency of contrast-enhanced (CE) whole body fluorodeoxyglucose (FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) protocol and non-CE (NCE) protocol. SUBJECTS AND METHODS: Ninety-three patients with known primary tumors underwent whole-body hybrid FDG PET/MRI during the follow-up of their malignancies with the use of NCE and CE protocols. The NCE PET/MRI protocol consisted of diffusion-weighted (b = 0 and 800 s/mm2) and T1-weighted Turbo Flash in the axial plane and T2-weighted HASTE sequence in the coronal planes (Σ = 25 min). The CE PET/MRI protocol was performed by acquiring axial serial CE 3D FS VIBE images in the upper abdomen, completing the whole body in the late phase in the axial plane (Σ = 30 min).
RESULTS: There was a statistically significant difference between the total number of lesions detected by the CE protocol (median 2, interquartile range (IQR) 0-14) and that detected by the NCE protocol (median 1, IQR 0-5; p < 0.001). More malignancies were detected in the abdomen (p < 0.001) and brain (p < 0.001) with the CE PET/MRI protocol, whereas no significant difference was present when comparing the 2 protocols in the detection of malignancies in the head and neck (p = 0.356), thorax (p = 0.09), lymph nodes (p = 0.196), and bone (p = 0.414).
CONCLUSION: The CE FDG PET/MRI protocol enables fast and accurate detection of malignancies compared to the NCE FDG PET/MRI protocol, particularly in the upper abdomen and brain. Diagnostic ability and time efficiency can be increased with the proposed short CE protocol in place of the whole body PET/MRI protocol including both NCE and CE imaging sequences.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Contrast medium; Fast protocol; Malignancy; Positron emission tomography/magnetic resonance imaging

Mesh:

Substances:

Year:  2019        PMID: 31203290      PMCID: PMC7024881          DOI: 10.1159/000501497

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  26 in total

Review 1.  MRI for response assessment in metastatic bone disease.

Authors:  F E Lecouvet; A Larbi; V Pasoglou; P Omoumi; B Tombal; N Michoux; J Malghem; R Lhommel; B C Vande Berg
Journal:  Eur Radiol       Date:  2013-03-01       Impact factor: 5.315

2.  Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.

Authors:  Hyo Jung Seo; Myeong-Jin Kim; Jong Doo Lee; Woo-Suk Chung; Yeo-Eun Kim
Journal:  Invest Radiol       Date:  2011-09       Impact factor: 6.016

3.  Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans.

Authors:  Philipp Lohmann; Gabriele Stoffels; Garry Ceccon; Marion Rapp; Michael Sabel; Christian P Filss; Marcel A Kamp; Carina Stegmayr; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur Radiol       Date:  2016-11-16       Impact factor: 5.315

Review 4.  Urinary bladder cancer: role of MR imaging.

Authors:  Sadhna Verma; Arumugam Rajesh; Srinivasa R Prasad; Krishnanath Gaitonde; Chandana G Lall; Vladimir Mouraviev; Gunjan Aeron; Robert B Bracken; Kumaresan Sandrasegaran
Journal:  Radiographics       Date:  2012 Mar-Apr       Impact factor: 5.333

5.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.

Authors:  Y Sugawara; S J Fisher; K R Zasadny; P V Kison; L H Baker; R L Wahl
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Authors:  Satoshi Takeuchi; Eric M Rohren; Reham Abdel-Wahab; Lianchun Xiao; Jeffrey S Morris; Homer A Macapinlac; Manal M Hassan; Ahmed O Kaseb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-12       Impact factor: 9.236

Review 7.  Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.

Authors:  Tobias Baumann; Christof Rottenburger; Guillaume Nicolas; Damian Wild
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-01-20       Impact factor: 4.690

8.  Added Value of Integrated Whole-Body PET/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT.

Authors:  Beomsik Kang; Jeong Min Lee; Yong Sub Song; Sungmin Woo; Bo Yun Hur; Ju Hyeon Jeon; Jin Chul Paeng
Journal:  AJR Am J Roentgenol       Date:  2016-01       Impact factor: 3.959

9.  Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors.

Authors:  Kazuhiro Kitajima; Yuji Nakamoto; Hiromi Okizuka; Yumiko Onishi; Michio Senda; Narufumi Suganuma; Kazuro Sugimura
Journal:  Ann Nucl Med       Date:  2008-08-29       Impact factor: 2.668

10.  Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.

Authors:  Emmanouil Panagiotidis; Alshaima Alshammari; Sofia Michopoulou; Evangelia Skoura; Keval Naik; Emmanouil Maragkoudakis; Mullan Mohmaduvesh; Mohammed Al-Harbi; Maria Belda; Martyn E Caplin; Christos Toumpanakis; Jamshed Bomanji
Journal:  J Nucl Med       Date:  2016-08-11       Impact factor: 10.057

View more
  1 in total

Review 1.  Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review.

Authors:  Alessio Smeraldo; Alfonso Maria Ponsiglione; Andrea Soricelli; Paolo Antonio Netti; Enza Torino
Journal:  Int J Nanomedicine       Date:  2022-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.